Format

Send to

Choose Destination
Blood. 2019 May 30;133(22):2374-2384. doi: 10.1182/blood.2018882233. Epub 2019 Mar 27.

How I treat chronic myeloid leukemia in children and adolescents.

Author information

1
Department of Pediatrics, Columbia University Medical Center, New York, NY; and.
2
Medical Faculty, Pediatric Hematology and Oncology, Technical University Dresden, Dresden, Germany.

Abstract

Evidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop similar recommendations in pediatrics. In addition to imatinib, which was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were recently approved for use in children, expanding the therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment of most pediatric cases. Yet, without sufficient data on efficacy and safety specific to pediatric patients, the selection of a TKI continues to rely on clinical experience in adults. Here, we present 4 case scenarios highlighting common yet challenging issues encountered in the treatment of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentation in advanced phases). Limited experience with very young children, the transition of teenagers to adult medicine, and the goal of achieving treatment-free remission for this rare leukemia are additional significant obstacles that require further clinical investigation through international collaboration.

PMID:
30917954
DOI:
10.1182/blood.2018882233

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center